Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results

Romero Laorden, N.Lorente, D.Lozano Mejorada, R.Sanchez-Soler, N.De Velasco, G.Puente, J.Borrega, P.Gonzalez-Billalabeitia, E.Castillo-Morales, V.Hernandez, A.Fernandez-Freire, A.Lopez Campos, F.Villatoro, R.Fernandez Calvo, O.Anido, U.Lainez, N.Luque, R.Ros Martinez, S.Castro, E.Olmos, D.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/24957enRole of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final resultsconference outputopen access10.1016/j.annonc.2021.08.11191569-8041https://doi.org/10.1016/j.annonc.2021.08.1119700527701070